Cargando…
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390898/ https://www.ncbi.nlm.nih.gov/pubmed/32463783 http://dx.doi.org/10.18553/jmcp.2020.26.6.782 |
| _version_ | 1785082578465718272 |
|---|---|
| author | Synnott, Patricia G. McQueen, R. Brett Ollendorf, Daniel A. Campbell, Jonathan D. Pearson, Steven D. |
| author_facet | Synnott, Patricia G. McQueen, R. Brett Ollendorf, Daniel A. Campbell, Jonathan D. Pearson, Steven D. |
| author_sort | Synnott, Patricia G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10390898 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103908982023-08-02 The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council Synnott, Patricia G. McQueen, R. Brett Ollendorf, Daniel A. Campbell, Jonathan D. Pearson, Steven D. J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2020-06 /pmc/articles/PMC10390898/ /pubmed/32463783 http://dx.doi.org/10.18553/jmcp.2020.26.6.782 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Synnott, Patricia G. McQueen, R. Brett Ollendorf, Daniel A. Campbell, Jonathan D. Pearson, Steven D. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_fullStr | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full_unstemmed | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_short | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_sort | effectiveness and value of rivaroxaban and icosapent ethyl as additive therapies for cardiovascular disease: a summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390898/ https://www.ncbi.nlm.nih.gov/pubmed/32463783 http://dx.doi.org/10.18553/jmcp.2020.26.6.782 |
| work_keys_str_mv | AT synnottpatriciag theeffectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT mcqueenrbrett theeffectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT ollendorfdaniela theeffectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT campbelljonathand theeffectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT synnottpatriciag effectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT mcqueenrbrett effectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT ollendorfdaniela effectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT campbelljonathand effectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueofrivaroxabanandicosapentethylasadditivetherapiesforcardiovasculardiseaseasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil |